Beryl Drugs

Who are in the management team of Beryl Drugs?

As of March 2023, the management team of Beryl Drugs includes Sanjay Sethi (Managing Director), Sudhir Sethi (Chairman), Abhinav Naik, and Shreya Saraf (both Independent Directors). Sanjay Sethi earns Rs. 21.0 lacs, while the other directors receive Rs. 40.0 k each, and Sudhir Sethi does not receive any remuneration.

As of March 2023, the management team of Beryl Drugs includes:<BR><BR>1. Sanjay Sethi - Executive Director / Managing Director / Promoter<BR>2. Sudhir Sethi - Chairman & Non-Executive Director<BR>3. Abhinav Naik - Independent Non-Executive Director<BR>4. Shreya Saraf - Independent Non-Executive Director<BR><BR>Sanjay Sethi is the only member with a specified remuneration of Rs. 21.0 lacs, while Sudhir Sethi does not receive any remuneration. Both Abhinav Naik and Shreya Saraf receive Rs. 40.0 k each.

Has Beryl Drugs declared dividend?

No Dividend History Available

Who are the peers of the Beryl Drugs?

Beryl Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ortin Global, Adline Chem Lab, Ganga Pharma, and Fabino Enter. Beryl Drugs has below-average management risk, growth, and capital structure compared to its peers, with a 1-year return of -38.52%.

Peers: The peers of Beryl Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ortin Global, Adline Chem Lab, Ganga Pharma., and Fabino Enter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted at Ortin Global, Ganga Pharma., Fabino Enter, and Beryl Drugs. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Ortin Global, Ganga Pharma., Fabino Enter, and Beryl Drugs. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, Average at Fabino Enter, and Below Average at Ortin Global, Adline Chem Lab, Ganga Pharma., and Beryl Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ortin Global has the lowest at -36.55%. Beryl Drugs' 1-year return of -38.52% is lower than both. Additionally, Ortin Global, Adline Chem Lab, Beryl Drugs, Ganga Pharma., and Fabino Enter all have negative six-month returns.

What is the technical trend for Beryl Drugs?

As of February 21, 2025, Beryl Drugs is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, alongside mildly bearish Bollinger Bands and Dow Theory signals.

As of 21 February 2025, the technical trend for Beryl Drugs has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly charts. The Dow Theory shows a mildly bearish stance on the weekly but no trend on the monthly, further supporting the bearish outlook.

What does Beryl Drugs do?

Beryl Drugs Ltd manufactures, sells, and exports branded and generic pharmaceuticals, classified as a Micro Cap company with a market cap of INR 11 Cr. As of March 2025, it reported net sales of 40 Cr and a net profit of 2 Cr.

Overview:<BR>Beryl Drugs Ltd is engaged in the manufacture, sale, and export of branded and generic pharmaceutical formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Beryl Drugs Ltd was incorporated on August 24, 1993, and acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 40 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.34<BR>- Return on Equity: 6.11%<BR>- Price to Book: 1.13<BR><BR>Contact Details:<BR>Address: 133 Kanchan Bag, Indore Madhya Pradesh: 452001 <BR>Tel: 91-731-25076375/3046366 <BR>Email: beryldrugs25@yahoo.com <BR>Website: http://www.beryldurgs.com

Who are the top shareholders of the Beryl Drugs?

The top shareholders of Beryl Drugs include promoter Sanjay Sethi with 10.88% and public shareholder Samir Narendra Gupta with 4%. Individual investors collectively hold 68.69%, with no institutional holdings or pledged shares reported.

The top shareholders of Beryl Drugs include Sanjay Sethi, who is the promoter with the highest holding at 10.88%. The highest public shareholder is Samir Narendra Gupta, holding 4%. Additionally, individual investors collectively hold a significant portion of the company at 68.69%. There are no institutional holdings or pledged promoter shares reported.

How big is Beryl Drugs?

As of 24th July, Beryl Drugs Ltd has a market capitalization of 10.00 Cr, with recent net sales of 21.14 Cr and a net profit of 0.58 Cr. The balance sheet for March 2024 shows shareholder's funds of 8.92 Cr and total assets of 17.38 Cr.

As of 24th July, Beryl Drugs Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Beryl Drugs reported Net Sales of 21.14 Cr and a Net Profit of 0.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 8.92 Cr and Total Assets of 17.38 Cr.

When is the next results date for Beryl Drugs?

Beryl Drugs will announce its results on 07 August 2025.

Beryl Drugs will declare its results on 07 August 2025.

Are Beryl Drugs latest results good or bad?

Beryl Drugs' latest results are mixed; while Profit After Tax has improved to Rs 0.17 crore, net sales fell by 23.36% and standalone net profit dropped by 94.59%, leading to a 'Strong Sell' rating from MarketsMOJO. Overall, the significant declines in key metrics indicate a more negative outlook.

Beryl Drugs' latest financial results present a mixed picture. On one hand, the company has shown an improvement in Profit After Tax (PAT), reporting Rs 0.17 crore for the latest six-month period, which is a notable increase from Rs 0.08 crore in the previous year. This suggests that Beryl Drugs is making progress in terms of profitability.<BR><BR>However, the overall performance for the quarter ending June 2025 has been challenging. The company experienced a significant decline in key metrics, with net sales dropping by 23.36% year-over-year and standalone net profit declining by a staggering 94.59%. Additionally, the Profit Before Tax (PBT) has reached its lowest point in five quarters, indicating a negative trend in near-term performance.<BR><BR>The stock is currently rated as a 'Strong Sell' by MarketsMOJO, reflecting the concerns surrounding its financial outlook. Overall, while there are some positive signs in profitability, the substantial declines in sales and profit metrics suggest that the results are more negative than positive.

Is Beryl Drugs overvalued or undervalued?

As of September 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 12.71 and an EV to EBITDA of 7.30, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date performance of -29.05%, as it has achieved a 3-year return of 168.59%, significantly outperforming the Sensex.

As of 2 September 2025, Beryl Drugs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 12.71, an EV to EBITDA of 7.30, and a ROCE of 10.96%. In comparison, its peers exhibit significantly higher valuations, such as Sun Pharma with a PE ratio of 32.69 and Divi's Lab at 70.48, indicating that Beryl Drugs offers a more favorable investment opportunity relative to its competitors.<BR><BR>Despite a challenging year-to-date performance of -29.05%, Beryl Drugs has shown resilience with a 3-year return of 168.59%, significantly outperforming the Sensex's 36.32% return during the same period. This suggests that the market may not fully recognize the company's potential, further supporting the conclusion that it is undervalued.

How has been the historical performance of Beryl Drugs?

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25, while total liabilities also fell from 17.39 Cr to 15.95 Cr during the same period. Cash flow from operating activities improved to 2.00 Cr in Mar'25, contrasting with previous years where it was zero. Overall, Beryl Drugs has experienced both growth and decline in various financial aspects, reflecting a complex performance trajectory.

Should I buy, sell or hold Beryl Drugs?

Why is Beryl Drugs Ltd falling/rising?

As of 01-Feb, Beryl Drugs Ltd's stock price has risen to 22.50, reflecting a 2.32% increase due to short-term gains and sector outperformance. However, the stock has faced significant long-term challenges, declining 36.62% over the past year, indicating underlying weaknesses despite its current valuation attractiveness.

As of 01-Feb, Beryl Drugs Ltd is experiencing a rise in its stock price, currently at 22.50, which reflects an increase of 0.51 or 2.32%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.79% today and has shown consecutive gains over the last two days, accumulating a total return of 2.41% during this period. <BR><BR>In the context of recent performance, the stock has demonstrated resilience, gaining 1.12% over the past week while the benchmark Sensex has declined by 1.00%. However, it is important to note that despite the recent positive movement, the stock has faced significant challenges over the longer term, with a substantial decline of 36.62% over the past year, contrasting sharply with the Sensex's gain of 5.16% during the same timeframe.<BR><BR>Additionally, while the stock is trading at a discount compared to its peers' average historical valuations, it has a relatively attractive valuation with a Return on Capital Employed (ROCE) of 11. This suggests that despite its recent gains, the company has underlying weaknesses, including a poor long-term growth rate and a weak ability to service its debt, which could impact future performance. <BR><BR>In summary, the current rise in Beryl Drugs Ltd's stock price is primarily driven by short-term gains and sector outperformance, despite the backdrop of long-term challenges and underperformance relative to the broader market.

Which are the latest news on Beryl Drugs?